XSHG
603077
Market cap2.62bUSD
Oct 09, Last price
2.23CNY
1D
1.83%
1Q
3.24%
Jan 2017
-4.18%
IPO
84.55%
Name
Sichuan Hebang Biotechnology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Chengdu, China, Sichuan Hebang Biotechnology Corporation Limited, which originated in 2002, operates as a multifaceted enterprise. The company's core activities revolve around the development and distribution of products spanning agricultural, chemical, and advanced materials sectors. Its agricultural portfolio features biological pesticides, veterinary biological pharmaceuticals, and methionine. Within the chemical division, key offerings include sodium carbonate, ammonium chloride, soda ash, diglyphosate, glyphosate, and brine. Additionally, the firm is a producer of various glass types, such as standard, smart, specialized, and low-emissivity coated glass, alongside photovoltaic packaging and module components. Another significant business line involves the supply of oil and natural gas. The company rebranded to its present name in April 2021, having previously been known as SichuanHebang Biotechnology Co.,Ltd.
Key people
Xiaoping Zeng
Chairman of the Board, General Manager · since 2023
Siying Jiang
Secretary of the Board · since 2023
Tian Chen
Director · since 2023
Zhenggang He
Director · since 2017
Jin Li
Director · since 2023
Xueling Qin
Director · since 2021
Jun Wang
Chief Financial Officer, Director · since 2023
Yang Hu
Independent Director · since 2020
Ying Song
Independent Director · since 2023
Changhua Yuan
Independent Director · since 2020
Headquarters & legal address
乐山市五通桥区牛华镇沔坝村
乐山市, SC 100000
CN
乐山市, SC 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||